M-CSF attenuates severity of chronic GVHD after unrelated BMT

Area of Science:

• Hematology
• Immunology
• Transplantation Medicine

Background:

• Unrelated bone marrow transplantation (BMT) is a critical treatment for hematologic malignancies.
• Graft-versus-host disease (GVHD), particularly chronic GVHD, remains a significant challenge impacting long-term outcomes.
• The role of colony-stimulating factors (CSFs) in modulating BMT outcomes requires further investigation.

Purpose of the Study:

• To evaluate the impact of M-CSF administration on long-term outcomes following unrelated BMT.
• To assess the effect of M-CSF on the incidence and severity of acute and chronic GVHD.
• To determine if M-CSF can attenuate the development of extensive chronic GVHD.

Main Methods:

• Retrospective analysis of data from the Japan Marrow Donor Program.
• Comparison of outcomes between 54 patients receiving M-CSF post-BMT and 500 control patients not receiving M-CSF or G-CSF.
• Multivariate and matched-pair analyses to identify significant factors influencing GVHD.

Main Results:

• No significant differences in overall survival (OS), acute GVHD, or relapse rates were observed between M-CSF and control groups.
• The incidence of chronic GVHD was comparable between the two cohorts.
• Extensive chronic GVHD occurred significantly less frequently in the M-CSF cohort compared to controls (RR: 0.73; 95% CI: 0.55-0.94; P=0.012).

Conclusions:

• M-CSF administration after unrelated BMT was associated with a significant reduction in extensive chronic GVHD.
• M-CSF shows potential as a clinical strategy to mitigate severe chronic GVHD.
• Further prospective studies are warranted to confirm the efficacy and safety of M-CSF in preventing severe chronic GVHD.